GB2572226A - Gout treatment - Google Patents

Gout treatment Download PDF

Info

Publication number
GB2572226A
GB2572226A GB1804763.9A GB201804763A GB2572226A GB 2572226 A GB2572226 A GB 2572226A GB 201804763 A GB201804763 A GB 201804763A GB 2572226 A GB2572226 A GB 2572226A
Authority
GB
United Kingdom
Prior art keywords
cartridge
hoop
treatment
gout
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1804763.9A
Other versions
GB201804763D0 (en
Inventor
Daavis Nigel
Coats Andrew
Tulloch Andrew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AAN MEDICAL Ltd
Original Assignee
AAN MEDICAL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AAN MEDICAL Ltd filed Critical AAN MEDICAL Ltd
Priority to GB1804763.9A priority Critical patent/GB2572226A/en
Publication of GB201804763D0 publication Critical patent/GB201804763D0/en
Publication of GB2572226A publication Critical patent/GB2572226A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying media, e.g. remedies, on the human body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

A method of treating gout comprising preparing a solution of colchicine and spraying the skin around the affected area. The solution may be 0.1-10 % colchicine in water, alcohol, or a mixture thereof. Also provided is a U- or hoop-shaped cartridge 10 for use in the treatment of gout where there is an internal container 16 containing a skin-penetrating drug effective against gout. The internal container 16 is connected to one or a plurality of nozzles 29 which project through the wall of the cartridge 10 inwards from the cartridge 10 towards the centre of the U or hoop. When pressure is applied to the internal container 16, the drug is expelled through the one or plurality of nozzles 29 into the centre of the U or hoop. The drug may be colchicine or a non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen, etoricoxib or diclofenac sodium.

Description

Technical Field [0001] This invention relates to method of treating gout.
Background Art [0002] Gout is a type of arthritis in which small crystals form inside and around the joints. It causes sudden attacks of severe pain and swelling. It's estimated that between 1 % and 2% of people in the UK are affected by gout and mainly affects men over 30 and women after the menopause. Overall, gout is more common in men than women.
[0003] Existing treatments for gout help relieve the symptoms and prevent further attacks. Treatment has been usually by injection, pills, and nasal sprays of drugs or other treatments. Some of the drugs act locally at the affected joint, whilst others aim to reduce the overall concentration of the chemicals that build up in the crystals. Many drugs cause side effects in the gut when taken orally and a high dose may be needed to achieve an effect at a peripheral target site. Local transdermal delivery of drug at or near its site of action may be preferable.
[0004] Colchicine is one of the drugs that acts locally at the affected site. Other suitable drugs include the NSAIDs. These can be formulated as a gel, but application of a gel to a gout-affected area can be excruciatingly painful. Furthermore, the amount applied and the frequency of use of creams and gels is very variable, particularly among the elderly. Existing treatments for gout help relieve the symptoms and prevent further attacks. Treatment has been usually by injection, pills, and nasal sprays of drugs or other treatments.
Disclosure of the Invention [0005] According to the present invention a method of treating gout comprises the steps of preparing a solution of colchicine and spraying the skin around the area affected by gout.
[0006] The solvent used would normally be water or alcohol or a mixture of water and alcohol.
[0007] In another aspect of the invention a cartridge for use in the treatment of gout comprises a cartridge shaped as a U or a hoop and having an internal container containing skin penetrating drug effective against gout joined to one or a plurality of nozzles projecting through the wall of the cartridge inwards from the cartridge towards the centre of the U or hoop, wherein application of pressure to the container expels liquid treatment through the one or plurality of nozzles in the cartridge.
[0008] In one example of the invention the skin penetrating drug is colchicine or a non-steroidal anti-inflammatory drug (NSAID).
[0009] Examples of suitable NSAIDs are ibuprofen, etoricoxib, and diclofenac sodium.
Brief Description of Drawings [0010] Figure 1 shows schematically a vertical section through a first exemplary dispensing device for use with this invention with a U-shaped cartridge containing a gout treatment in solution; ;
[0011] Figure 2 shows the first exemplary dispensing device this time with a hoop cartridge containing a gout treatment in solution mounted on a base, the base being in section;
[0012] Figure 3 is a side view in partial section of a second exemplary dispensing device for use with this invention with a hoop cartridge containing a gout treatment in solution;
[0013] Figure 4A is a detail view of a nozzle of figure 3 seen from inside the hoop; [0014] Figure 4B is a cross section of the nozzle and hoop on the line A-A’ of figure 4A;
[0015] Figure 5 is a side view in partial section of a different arrangement of the second example of the invention;
[0016] Figure 6 is a side view of a third exemplary dispensing device for use with this invention with a cartridge containing a gout treatment in solution;
[0017] Figure 7 is a side view in partial section of one arrangement of the third exemplary dispensing device with a cartridge containing a gout treatment in solution;
[0018] Figure 8A is a section on the line B-B’ of figure 7 prior to release of a treatment;
[0019] Figure 8B is a section on the line B-B’ of figure 7 after release of a treatment; and [0020] Figure 9 is a side view in partial section of a further arrangement of the third exemplary dispensing device with a cartridge containing a gout treatment in solution;
[0021] Figure 10 is a schematic cross section of a fourth exemplary dispensing device with a disposable cartridge in which a pump and gout treatment container are both mounted in a disposable cartridge;
[0022] Figure 11 shows the cartridge of figure 10 interacting with a base station; [0023] Figure 12 shows a fifth example of the invention with a U-shaped cartridge which may contain gout treatment in solution which can be opened vertically, and shown open to show individual components; and [0024] Figure 13 a schematic vertical section though the cartridge of figure 12 when closed and mounted in a base.
Examples of the invention and of a dispenser for treatment of gout [0025] Figures 1 and 2 show cartridge 10 (U-shaped in figure 1 and hoop shaped in figure 2). In figure 1 the cartridge is in section. In figure 2 the cartridge 10 is shown mounted on a base 40, which is in section.
[0026] A gout treatment namely colchicine is dissolved as a 0.1 % to 10%, depending on the potency required, solution in water, alcohol or a water alcohol mixture and the solution placed in a cartridge 10 as shown in figures 1 or 2. As an alternative similar concentration solutions of ibuprofen, etoricoxib, or diclofenac sodium in water, alcohol or water and alcohol.
[0027] In figure 1, the cartridge 10 containing the gout treatment 18 is U-shaped with arms 11 and 12 extending upwards from the bottom of the U 13. In figure 2 arms 11 and 12 are sides of a substantially rectangular hoop, the arms 11 and 12 being joined bottom 13 and top 15; as shown the hoop has its sides 11 and 12 longer than the bottom and top 13, 15, but it has been found that some users prefer a hoop structure in which the bottom and top 13 and 15 are longer than the sides 11 and 12.
[0028] Returning to figure 1, a container clip 14 is provided in the bottom 13 of the U in which a container 16 containing the gout treatment 18 is mounted. The container 16 may be a bottle, but preferably is a deformable bag as shown. The container is connected to a displacement actuator 19. The actuator 19 has a chamber 20 with a piston 21 operating to and fro within the chamber 20. There is one way valve 22 between the container 16 and chamber 20. The piston 21 is connected to a cam 23 operated by a micro motor 24. A half turn of the motor drives the piston to draw liquid treatment 18 from the container 16 through the one way valve 22 into the chamber
20. A further half turn of the motor, drives the treatment from the chamber 20 through a further one way valve 26 and connector 27 into a pair of tubes 28, one of the pair passing through one arm 11 of the cartridge 10 the other through the other arm 12 each to nozzles 29 directed inwards from the arms 11 and 12.
[0029] Infrared lamp 30 and receiver 31 are mounted on the arms 12 and 11 opposite one another to detect the presence of a body part between them.
The receiver 31 connects to a switch 32 which controls power to the motor 24, the motor being switched on when the IR beam 33 is broken and thus the receiver 31 detects the presence of a body part between the arms 11 and 12.
[0030] The container 16 optionally may have a NFC or RFID chip 36 attached. The chip could contain information about the content of the container, the required usage, date of manufacture, serial number and/or expiry date for example.
[0031] The cartridge 10 containing the gout treatment is supplied to a patient as a sealed disposable unit which connects to a base, identical to item 40 shown in figure 2.
[0032] Figure 2 shows a variant of the geometry of the cartridge 10, here the cartridge is a closed generally rectangular hoop rather than a U-shape open at the top. The bottom 13 of the hoop contains exactly the same items as described in figure 1 with liquid connections for treatment to flow to the nozzles 29. The cartridge 10 is shown in figure 2 connected to a base 40.
[0033] The base 40 has a socket 42 to receive pins of a plug 38 at the base of the cartridge 10. The socket 42 is connected to a mains transformer 44 which provides power through the plug and socket 38/42 to the infra-red lamp 30 and detector 31 and the motor switch 32 (see figure 1). It also powers a date chip 45 and microprocessor 46.
[0034] Experience has shown that power is best supplied though a mains connection to the transformer 44. However it is feasible to replace the mains connection and transformer with a battery. Such a battery can provide power through the plug and socket 38/42 to the motor switch 32 and infra-red lamp 30 and detector 31. The motor switch 32 (figure 1) and the infra-red lamp 30 and detector 31 could be powered by a separated battery mounted in the cartridge, but this may lead to complications in disposal of cartridges after use and is less reliable.
[0035] With power provided through the base 40, when the cartridge 10 is mounted in base 40 and the detector combination 31 detects that a body part is place between the arms 11/12 of cartridge 10, the switch 32 powers the motor 24 driving the cam 23 to operate piston 21, by turns drawing gout treatment 25 from container 18 into chamber 20 and then expelling it, through valve 26 into tubes 11 and 12 and thus through nozzles 29, so spraying the gout treatment 25 onto the body part concerned (see figure 1).
[0036] By monitoring the power supply through plug and socket 38/42, the microprocessor 46 can monitor the number of times the motor 24 is operated and the period of operation. This information can be merged with the date chip to provide also information on the date and time of operation. Combining that with information received from the NFC/ RFID chip 36 on the container 16, the microprocessor can calculate the volume of treatment left in the container, compliance by the patient with the dosing regimes, and to display the information on a display 52, to operate an alarm when a treatment is due, or transmit the information through a further NFC or RFID chip 54 to a remote monitoring station 56 which can check on the patient and his/her needs resupplying treatments as needed. The microprocessor 46 can also prevent power reaching the motor 24 if a gout treatment is requested too soon after a previous treatment.
[0037] As an alternative to or in addition to an NFC/RFID chip on container 16, the base 40 may have a scanner or bar code reader which reads a bar code label or chip attached to the cartridge 10: the bar code containing information to identify the date of manufacture of the treatment, the nature of the treatment and dosage quantities and frequencies. A similar system is described below in relation to figures 6 to 8.
[0038] Furthermore means can be provided in the system whereby the patient identifies themselves; for example this can be by insertion by the patient of a code, or by the patient wearing a tag or communication device which must be recognised by the microprocessor.
[0039] As noted previously, it is preferred that the container 16, in the embodiment of figures 1 and 2, is a deformable bag. If the container 16 is not deformable, an air supply will be needed to the container, to replace gout treatment from the container which has been expelled, otherwise low pressure in the container 16 will prevent satisfactory operation.
[0040] The cartridge 10 is disposable; but could be returned to a pharmacist for cleaning and reuse if that is preferred.
[0041] The nozzles 29 can be set up to remain closed until the pressure in the hoop has reached the desired operating pressure to prevent premature operation of the spray.
[0042] In figure 3 and 4, a dispenser 100 comprises a cartridge 101 having a circumferential disposable deformable bag 102 mounted in a hoop 104. The wall of the bag divides the cartridge 101 into an inner chamber 109 containing a gout treatment 108 and a chamber107 around the inner chamber 109. The bag, when mounted in the hoop, has one or more nozzles 106 directed inwardly towards the centre of the hoop. The hoop is divided vertically into two halves 104A and 104B vertically, the two halves being clipped together top and bottom of the hoop using clips 138.
[0043] The hoop 104 has one or more apertures 110 in which the nozzles 106 are mounted. The outside surface of the nozzles 106 have a waist 111 holding a seal 112 held to form a gas tight joint against the inner perimeter of the apertures 110.
[0044] The hoop has a connector 114 to the chamber107 which, when the hoop is mounted in stand 116, forms an air tight joint onto the outlet 118 of a pump 120. In operation, the pump 120 draws air in from the surrounding atmosphere through an inlet duct 122, and pumps it under pressure into the chamber107 around the deformable bag 102. The pressurised air surrounding the bag102 deforms it, forcing some or all of the gout treatment 108 to be expelled as a spray 115 though the nozzle(s) 104.
[0045] The hoop has a scanner or bar code reader 124 which reads a bar code label or chip 126 attached to the cartridge 101. The latter contains information about the content of the cartridge 101. This information is fed by a multiplex link 128 to a programmable chip 130, connected to the hoop by a connection 129.
[0046] The pump 120 is powered from a battery or mains source 132. In most cases the pump 120 would be triggered by one or more sensors 134 cooperating with the programmable chip mounted on the hoop 102 and facing inwards to identify the presence of, orientation and form of a body part placed within the hoop 102. The sensors are connected though wire links (not shown for clarity) to the connector 129 and thus to multiplex link 128. A switch 135 operated through an aperture 136 in the base of the stand 116 can be used to turn the pump on and off pressurising the hoop 104. However, the switch 135 in some arrangements may more conveniently be placed on the side of the base or isolated from user intervention altogether within the case.
[0047] The programmable chip 130 is set up to reflect the specific needs and doses required to be given to person or animal. In particular the programmable chip 130 can be set to limit the length of time during which the pump is switched on and/or to prevent operation of the pump 120 for a pre-set period following its previous operation. The programmable chip may also be programmed to vary the pressure delivered by the pump and thus the density and spread of any spray ejected through the apertures 106.
[0048] As a further development, the programmable chip 130 is linked to the internet to inform a chemist or carer etc., that a bag has been loaded and the nature of its content. It can also be used to inform doctors, nurses, or carers of the time that the device was operated and the duration of the operation. Furthermore, it could be used to activate an alarm if a treatment was not administered at the right time.
[0049] In a further refinement, a chip or reader, facing inward from the hoop reads a bar code or radio frequency identification (RFID) tag on a patient or animal as a means of primary identification that the anticipated person or animal is inserting a body part into the hoop for treatment. If the correct code or tag is not identified, the programmable chip will not allow the pump to operate.
[0050] After the gout treatment (or when exhausted), the hoop 104 is removed from the stand 116 and the bag 102 is removed from the hoop 104, by opening clips 108 to separate the two halves 104A and 104B of the hoop. The bag 102 is then replaced, with the nozzles 106 of the new bag being located in the apertures 110 of the hoop 102. In this arrangement the bag containing the gout treatment forms a disposable cartridge.
[0051] The stand 116, pump 130, and other components mounted in the stand 116 do not come into contact with the liquid treatment 108 and do not require cleaning to medical standards, the bag is disposable and only the hoop 104 needs to be cleaned to medical standards if it is reused.
[0052] This minimisation of cleaning can be taken one step further, by gluing the two halves of the hoop 104A and 104B together and eliminating clips 108, making the hoop 104 containing the bag 102 itself the disposable after use.
[0053] The nozzles 106 can be set up to remain closed until the pressure in the hoop has reached the desired operating pressure to prevent premature operation of the spray.
[0054] In figure 5, the dispenser 100 comprises a cartridge 101 as shown in Figure 3 but with the parts of the hoop 104 glued together. The cartridge 101 contains gout treatment. The clip (138 in figure 3) is thus eliminated. In this example too, the sensors (134 in figure 3) are omitted.
[0055] Rather than being mounted on a base (116 in Figure 3) the cartridge 101 is mounted on a gas container 150. Normally the gas cylinder or cartridge contains compressed air, but other suitable compressed gases could be used. The gas container 150 has a control valve 152, this is shown as hand operated, but in other arrangements, the gas container 150 could be a single discharge device discharging the correct volume of gas into the chamber 107 for a single operation of the dispenser, after which the cartridge including gas container 150 is thrown away.
[0056] It can be seen that the embodiment of figure 5 avoids the need to clean any apparatus to medical standards after use.
[0057] Another example of the invention is shown in figure 6. Here a dispenser 200 is formed of a cartridge 201 comprising a hoop 204 divided internally by a deformable elasticated diaphragm 202. The cartridge is operated manually. It is a very simple device, operated manually by breaking a seal 214.
[0058] The hoop 204 and a diaphragm 202 are supplied as a sealed cartridge 201. The diaphragm 202 divides the cartridge into two; a container209 containing the gout treatment 208 and an outer chamber 207. The hoop has a flat inner wall 205 in which nozzles 206 are mounted having airtight seals within apertures 210 in the hoop 204. The diaphragm 202 is made of an elasticated material, such as medical grade silicon rubber, and is mounted in the hoop so that in its upstretched configuration it stretches across the inside of inner wall 205. The hoop 204 is air tight and chamber 207 is evacuated of air through duct 212 on assembly so that the diaphragm 202 stretches. The duct 212 is then sealed with a seal 214. As the evacuation occurs, the gout treatment 208 is admitted into the container 209 between the expanded diaphragm 202 and the inside of the inner wall 205 of the hoop through an aperture 211 in the inner wall 205; the aperture 211 is then permanently sealed off. The gout treatment 208 is thus held in place between the diaphragm and the inside of inner wall 205 under the influence of the vacuum formed in the chamber207 after evacuation of air acting on diaphragm 202.
[0059] The cartridge 201 is placed around a body part to be treated and the seal 214 broken admitting air into the chamber207. The vacuum holding the diaphragm 202 in its stretched state is thus lost and diaphragm 202 relaxes to its unstretched position, forcing the gout treatment 208 out through nozzles 206 as a spray 215 onto any body part inserted in the hoop 204. After treatment, the cartridge 201 and content is disposed of.
[0060] The nozzles 206 close when the pressure in the container 209 drops below a predetermined level, to prevent any residual gout treatment dribbling out of the cartridge 201.
[0061] This embodiment is disposed of after use and thus requires no cleaning to medical standards.
[0062] The embodiment in figure 6 is developed further in figures 7 and 8. [0063] In figures 7 and 8, the cartridge 201 is mounted on a base 216.
[0064] The base 216 has a scanner or bar code reader 224 which reads a bar code label or chip 226 attached to the cartridge 201. The bar code label contains information about the content of the cartridge 201. This information is fed by a multiplex link 228 to a programmable chip 230, where the information can be stored. But as a further development, the programmable chip 230 has an internet connection which can be used to inform a chemist or carer etc., that a cartridge 201 has been loaded and the nature of its content. It can also be used to inform doctors, nurses, or carers of the time that the device was operated. However, in this arrangement the duration of the operation is fixed and is set by the specific design and content of the cartridge 201. Furthermore, the programmable chip could be used to activate an alarm if a treatment was not administered at the right time.
[0065] The base has a servo operated pin 231 to break the seal 214, the servo mechanism 232 controlling the pin 231 being controlled by the programmable chip 230 to break the seal 214 when sensors 234 disposed around the inside of the hoop 204 detect the presence of a body part to be treated within the hoop. Typically the sensors 234 are chips or reader facing inward from the hoop to read a bar code or radio frequency identification (RFID) tag on a patient or animal as a means of primary identification that the anticipated person or animal has inserted the correct body part into the hoop for treatment and it is in the right position. This information is fed to the programmable chip 230; only if the correct code or tag is identified will the programmable chip allow the pin 231 to move to break the seal 214.
[0066] A body part to be treated is placed within the hoop 204. The vacuum in chamber 207 holding the diaphragm 202 in its stretched state is broken by breaking seal 214, the diaphragm then relaxes (as in figure 8B) forcing the treatment out through nozzles 206 as a spray 215 onto the body part to be treated. After treatment, the cartridge 201 and content is removed from the base 216 and disposed of. The nozzles 206 close when the pressure in the container 209 drops below a predetermined level, to prevent any residual gout treatment dribbling out of the cartridge 201.
[0067] Figure 9 shows a further development of the arrangements of figure 7 and
8. Here, the dispenser 200 comprises a cartridge 201 as described in figures 6 and 7; the cartridge, however, has only one nozzle 206.
[0068] The cartridge 201 is mounted using clips 218 within a circular electrically conducting disc 236, for example an aluminium disc. The disc 236 is mounted vertically in a frame 242, supported top and bottom on rollers 244. At the base of the frame either side of the disc 236 are electromagnets 240. Supply of current from a power pack 241 to the electro magnets 240 induces eddy currents in the disc 236 causing it to rotate, in a way similar to the rotating disc of an electricity meter. The disc 236 and elector-magnets in combination form an induction motor 238 to rotate the cartridge 201. The frame 242 is mounted on a base 216 which has a programmable chip 230 with internet connections as discussed in with respect to figure 5.
[0069] The base 216 has a servo operated pin 231 to break the seal 214, the servo mechanism 232 controlling the pin 231 being controlled by the programmable chip 230 to break the seal when sensors 234 disposed around the inside of the hoop 204 detect the presence of a body part to be treated within the hoop. Typically the sensors 234 are chips or readers facing inward from the hoop to read a bar code or radio frequency identification (RFID) tag on a patient or animal as a means of primary identification that the anticipated person or animal has inserted the correct body part into the hoop for treatment and it is in the right position. The sensors 234 are linked to the programmable chip 230 by a transmitter and receiver 229A and 229B mounted on the cartridge 204 and stand 216 respectively and by multiplex cable 228. The programmable chip also controls the power supply from power pack 241 to the electro-magnets 240, power not being supplied to the electro-magnets 240 and the induction motor 238 not operated until the sensors 234 detect the presence of the appropriate body part.
[0070] The cartridge 201 is placed around a body part to be treated and the seal 214 broken by pin 231. The vacuum in chamber207 holding the diaphragm 202 in its stretched state is lost and diaphragm 202 relaxes, forcing the gout treatment 208 out through the single nozzle 206 as a spray 215 onto the body part to be treated as the cartridge 201 rotates with disc 236. The nozzle 206 closes when the pressure in the container 209 drops below a predetermined level, to prevent any residual gout treatment dribbling out of the cartridge 201.
[0071] After treatment, the clips 218 holding cartridge 201 are opened and the cartridge 201 removed and disposed of.
[0072] In the examples of figures 6 to 9, the cartridge 201 and contents can only be used once and the container therein contains substantially the exact liquid treatment required. All these examples avoid the need to clean any supporting apparatus, such as a stand or pump to medical standards as no other such equipment comes into contact with the treatment.
[0073] Figures 10 and 11 show a further example of the invention being a development of the concepts in figures 7 and 8, but simplified to reduce production costs and making the dispenser easier to use. A dispenser 300 comprises a hoop shaped cartridge 301 having an opposed pair of nozzles 318.
[0074] Within the cartridge an electronic pump 302 and fluid container 308, containing gout treatment. The pump is connected electrically 306 to a power source though and electric/data connector 326 in the lower leg of the cartridge 301. Powering the pump drives air through silicon connecting pipe 304 into the fluid container 308, expelling treatment from the fluid container 308 into silicon connecting pipe 312 though a one way valve 310 which prevents reverse flow of the treatment. The connecting pipe 312 leads to a manifold 314 splitting the fluid flow into two along silicon connecting pipes 316 to nozzles 318. From the nozzles the treatment is expelled as a spray towards the centre of the cartridge 301 and onto any body part instead into the centre of the cartridge. Normally the design of pipes 312 and 316 is such that the distance travelled by gout treatment from the container 308 to the both nozzles is roughly equal to avoid any pressure differences between the sprays emanating from the nozzles.
[0075] A base station 330 is provides having an upstanding plug 328 onto which the electric/ data connector 326 locates to hold the cartridge 301 in place. A valve 327 seals the cartridge 301 when the cartridge 301 is not connected to the base station, so that the inside of the cartridge is never open to the environment.
[0076] The plug 328 provides power to the cartridge from a mains transformer 331 though a connection 332; it also provides a data link to and from the pump from a programmable chip 333 through data connection 334.
[0077] The programmable chip 333 also may have NFD capability so that it can be monitored and controlled remotely if desired.
[0078] The programmable chip can also control the times at which the transformer 322 can be on, and thus availability of power to the pump 302; in addition or alternatively it can prevent power being supplied to the pump for a pre-set period after previous usage of the cartridge.
[0079] Operation of the dispenser in figures 10 and 11 is simplified as no sensors are incorporated in the cartridge itself; rather the base station has one or more infra-red sensors broken by hand to turn on the electricity supply from the transformer. This can be done through the programmable chip 333 or by direct switching on of the transformer 331.
[0080] Operation pf the pump and thus consumption of gout treatment is monitored though the data link 307 between the pump 302 and the connecor326 through plug 328 and data connection 334. Monitoring of usage will alert staff to the need to replace the cartridge 301 or when the dispenser is being used otherwise than in accordance with instruction or a prescription.
[0081] More sophisticated controls can be employed in the embodiment of figures 10 and 11, including sensors in the inward facing walls of the cartridge as shown in figures 1 and 2. Instead of a hoop, the cartridge 301 of figures 10 and 11 could be U-shaped as shown in figure 1. Instead of the pump 302 pumping air into the gout treatment in container 308, it could be arranged in the pipe 312 to pump gout treatment from the fluid container 308.
[0082] Actuation of the dispenser 300 shown in figures 10 and 11 is by triggering infra-red sensors in the base; other means can be substituted, such as finger or palm print recognition, or voice recognition, or PIN actuation: however these would tend to increase price and may not be so easy to use by vulnerable patients. Similarly a system of cartridge recognition may be incorporated in the base as previously described so that the pump can only receive power if the cartridge contains a treatment which is expected - preventing cartridges containing other that prescribed treatments being operable.
[0083] In the examples of figures 6 to 11, the cartridges 201/301 and contents can only be used once and the container therein contains substantially the exact liquid treatment required. All these examples avoid the need to clean any supporting apparatus, such as a stand or pump to medical standards as no other such equipment comes into contact with the treatment.
[0084] A further example of the invention is shown in figures 12 and 13 which avoids the need to dispose of the cartridge and associated items after use, and therefore, possibly is a lower cost option.
[0085] Figures 12 and 13 show s dispenser 400 according to the invention with a cartridge 401 which in figure 13 is mounted in a base 340.
[0086] The cartridge 401 is U shaped with arms 411 and 412, and is split vertically into two halves 413 and 414. In one half 413, a container418 containing gout treatment 422 is mounted in a moulding 416. The container 418 has a plunger cap 420 depression of which forces gout treatment 422 from the container 418. The outlet 424 of the plunger cap 420 is connected to a pair of tubes 426, one passing through one arm 411 of the cartridge the other through the other arm 412 each to nozzles 428 directed inwards from the arms 411 and 412.
[0087] The container 418 optionally may have a NFC or RFID chip 419 attached. The chip could contain information about the content of the container, the required usage, date of manufacture, serial number and/or expiry date for example.
[0088] The cartridge 401 is supplied to a patient as a sealed unit, screws 429, or as an alternative clips, hold the cartridge together, so that it can be used as a returnable unit, refilled and cleaned by a pharmacist or supplier.
[0089] The base 440 has a depression 441 in its upper surface matching the outer shape of the cartridge 401 where the cartridge is mounted in the base. A socket 442 is provided in the depression 441 to receive and connect with a plug 430 on the bottom of the U of the cartridge 401, the plug and socket being to support the cartridge 401 in place in the base 440. If desired infra-red lamp and detector can be provided to sense the presence of a body part between the arms 411 and 412 of the U as shown in figure 1, and if so the plug and socket can provide power from a rechargeable or replaceable battery (which can be rechargeable or replaceable) 444 in the base 440. The battery 444 also powers a date chip 445 and microprocessor 446 and actuator 448. The actuator 448 has an arm 450 extending from the surface of the base in the depression through a slot 438 in the cartridge to engage against the plunger cap 420 of container 418.
[0090] As an alternative to the infra-red lamp and detector, an infra-detector may be placed on the base unit and operated by hand as described with reference to figure 11. Other methods of triggering operation of the device will be clear to the shilled designer.
[0091] However operation is triggered, the microprocessor 446 allows the battery 444 to power the actuator 448 whose arm 450 presses the plunger cap 420 releasing treatment 422 from the container 418 to the nozzles 428 through tubes426, so spraying the treatment 422 onto the body part concerned.
[0092] The microprocessor 446 can monitor the number of times the actuator is operated and the period of operation, and thus combining that with information received from the NFC/ RFID chip 436 on the container 418, can calculate the volume of gout treatment left in the container, compliance by the patient with the dosing regimes, and to display the information on a display 452, to operate an alarm when a treatment is due, or transmit the information through a further NFC or RFID chip 454 to a remote monitoring station 456 which can check on the patient and his/her needs resupplying treatments as needed. The microprocessor 446 in combination with the time chip 445 can also prevent operation of the actuator 448, if a treatment is requested too soon after a previous treatment. Furthermore means can be provided in the system whereby the patient identifies themselves; for example this can be by insertion by the patient of a code, or by the patient wearing a tag or communication device which must be recognised by the microprocessor.
[0093] Other arrangements can be derived for controlling the operation of the arm 450. In particular, it is possible to use a servo motor in the cartridge to drive a small pump to pump liquid from a container of liquid in the cartridge, to pump treatment into the tubes 426 (as seen in figures 10 and 11). To ensure even spray from each nozzle 428, an individual servo motor can be associated with each individual tube 426.
[0094] In the example of figures 12 and 13, the battery 444 can be replaced with a transformer; likewise where a transformer is described in the other examples, it can be replace by a batter (rechargeable or one use) [0095] In each of the examples above provided with a programmable chip, the chip can be programme not to operate unless a pre-set time has passed since a previous treatment to prevent over frequent application of treatments.
[0096] The forgoing examples show a number of ways in which the invention may be implemented, it is emphasised that the invention is not limited to the particular examples given.
[0097] Control of ejection of the gout treatment in the apparatus of figures 1 to 13, may also be through a face recognition system, where by the relevant pump or motor does not operate until a facial recognition system associated with the apparatus identifies that the proposed user is the correct user for the treatment by recognising the proposed users face and provides one unlocking signal. Other controls, such as means to identify that a body part is in the U or hoop would still be used too.
[0098] In each case the relevant pump or motor does not turn on unless the correct user is identified by the facial recognition system.

Claims (6)

Claims
1. A method of treating gout comprising the steps of preparing a solution of colchicine and spraying the skin around the area affected by gout.
2. A method according to claim 1 in which the solvent is water or alcohol or a mixture of water and alcohol.
3. A method according to claim 1 or 2 in which colchicine is present in solution in the range 0.1-10% inclusive by weight.
4. A cartridge for use in the treatment of gout comprises a cartridge shaped as a U or a hoop and having an internal container containing skin penetrating drug effective against gout joined to one or a plurality of nozzles projecting through the wall of the cartridge inwards from the cartridge towards the centre of the U or hoop, wherein application of pressure to the container expels liquid treatment through the one or plurality of nozzles in the cartridge.
5. A cartridge according to claim 4 in which the skin penetrating drug is colchicine ora non-steroidal anti-inflammatory drug (NSAID).
6. A cartridge according to claim 5 in which the NSAID is one of ibuprofen, etoricoxib, and diclofenac sodium.
GB1804763.9A 2018-03-24 2018-03-24 Gout treatment Withdrawn GB2572226A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1804763.9A GB2572226A (en) 2018-03-24 2018-03-24 Gout treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1804763.9A GB2572226A (en) 2018-03-24 2018-03-24 Gout treatment

Publications (2)

Publication Number Publication Date
GB201804763D0 GB201804763D0 (en) 2018-05-09
GB2572226A true GB2572226A (en) 2019-09-25

Family

ID=62067915

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1804763.9A Withdrawn GB2572226A (en) 2018-03-24 2018-03-24 Gout treatment

Country Status (1)

Country Link
GB (1) GB2572226A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021205165A1 (en) * 2020-04-08 2021-10-14 Aan Medical Limited Hand sanitiser monitor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03148218A (en) * 1989-11-02 1991-06-25 Nissan Chem Ind Ltd Colchicine-containing external preparation
US6399093B1 (en) * 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
CH699814B1 (en) * 2007-05-14 2010-05-14 Mepha Ag Diclofenac for topical application as a spray.
CN102366403A (en) * 2011-10-10 2012-03-07 薛巍 Colchicine microemulsion transdermal agent, preparation method thereof and application thereof
WO2016011104A1 (en) * 2014-07-18 2016-01-21 Gensco Laboratories, Llc Homeopathic topical gel for transdermal delivery of colchicine formulations and method of use
CN108057018A (en) * 2016-11-08 2018-05-22 北京人福军威医药技术开发有限公司 Colchicin topical composition and preparation method thereof
WO2018200143A2 (en) * 2017-04-25 2018-11-01 Reyoung Corporation Compositions of schisandra extracts and methods thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03148218A (en) * 1989-11-02 1991-06-25 Nissan Chem Ind Ltd Colchicine-containing external preparation
US6399093B1 (en) * 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
CH699814B1 (en) * 2007-05-14 2010-05-14 Mepha Ag Diclofenac for topical application as a spray.
CN102366403A (en) * 2011-10-10 2012-03-07 薛巍 Colchicine microemulsion transdermal agent, preparation method thereof and application thereof
WO2016011104A1 (en) * 2014-07-18 2016-01-21 Gensco Laboratories, Llc Homeopathic topical gel for transdermal delivery of colchicine formulations and method of use
CN108057018A (en) * 2016-11-08 2018-05-22 北京人福军威医药技术开发有限公司 Colchicin topical composition and preparation method thereof
WO2018200143A2 (en) * 2017-04-25 2018-11-01 Reyoung Corporation Compositions of schisandra extracts and methods thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Singapore Medical journal, 53(11), 2012, Sairam Maduri and Venkateshwar Reddy Atla, "Formulation of colchicine ointment for the treatment of acute gout" pages 750-754, available via: www.smj.org.sg/sites/default/files/5311/5311a7.pdf *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021205165A1 (en) * 2020-04-08 2021-10-14 Aan Medical Limited Hand sanitiser monitor

Also Published As

Publication number Publication date
GB201804763D0 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
TWI606821B (en) Medicament delivery device
US20160158465A1 (en) Dispenser
CN101495080B (en) Drug storage and dispensing devices and systems comprising same
CN104905955B (en) Gynaecology's episioitis fumigation treatment device
JP6499160B2 (en) Cartridge for substance delivery module
EP4240464A1 (en) Devices, systems and methods for treating the skin
CN101827625A (en) Semi-automatic emergency medication dose nebulizer
CA2921661C (en) Measured dose dispenser
US11534586B2 (en) Liquid treatment dispenser
US20200055620A1 (en) Transport and Transfer Container for a Liquid Medium
NO336841B1 (en) Drug delivery device with display indicating the state of an internal drug reservoir
CN103338737B (en) Pressurized aerosol bath method and pressurized aerosol bath system
GB2572226A (en) Gout treatment
CN207450809U (en) A kind of hospital's sterilization steps on dustbin with foot
GB2572748A (en) Treatment dispenser
CN107405634B (en) Dispenser
CN103347479A (en) Gas mist pressure bathing method and gas mist pressure bathing system
US20240109086A1 (en) Disposable cartridges for electrospraying applicators, systems, and methods thereof
CN108190483A (en) Robot carrying equipment component
KR101008674B1 (en) Container and scalp massager with the container
CN116328113B (en) Clinical atomization pressurizing medicine spraying device for respiratory diseases
CN221394772U (en) Open box convenient for ophthalmologic inpatients to place eyedrops
AU2023316918B2 (en) Disposable cartridges for electrostatic applicator, systems, and methods thereof
KR20120106418A (en) Sterilizer for portable
CN2272755Y (en) Pneumatic automatic quick doser

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)